Market Insights
The global influenza therapeutics market is anticipated to grow significantly during the forecast period due to the growing prevalence of influenza, increasing demand for treatment medication, and government initiatives in awareness and treatment that will drive the growth of the influenza therapeutics market globally.
The report titled “Influenza Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall influenza therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on technology and different geographical regions.
Geographically, the global influenza therapeutics market is studied for the following regional markets:
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global influenza therapeutics market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the competitive landscape of the global influenza therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global influenza therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global influenza therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on therapy type, the global influenza therapeutics market is segmented as follows:
- Vaccines
- Trivalent
- Quadrivalent
- Drugs
- Zanamivir
- Oseltamivir
- Peramivir
- Other
Influenza is an acute respiratory disease caused by influenza A, B or C virus infection; it is preventable by vaccination or chemoprophylaxis and is treatable by specific antiviral drugs. The World Health Organization (WHO) reports that throughout the world, annual outbreaks result in 3–5 million severe cases and between 250,000 and 500,000 deaths. Currently, influenza vaccines (also known as flu shots or jabs) dominate the global influenza market because government initiative for vaccination is a prime factor driving the growth of the influenza vaccine market globally. The World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and European Centre for Disease Prevention and Control recommend yearly vaccination for nearly all people over the age of six months, especially those at high risk. For the treatment of influenza, the CDC recommends oral oseltamivir (Tamiflu), inhaled zanamivir (Relenza), and intravenous peramivir (Rapivab) antiviral medications, as well as trivalent and quadrivalent vaccines; all of these factors are contributing to the global influenza market’s growth.
For the purpose of this study, the global influenza therapeutics market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
The World Health Organization (WHO) reports that throughout the world, annual outbreaks result in 3–5 million severe cases and between 250,000 and 500,000 deaths due to influenza infection. It is observed that, currently, North America is followed by Europe in dominating the global influenza market because government initiatives such as the Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control recommend yearly influenza vaccination for nearly all people over the age of six months, especially those at high risk, which are primarily driving the growth of the influenza market in these regions. Also, some factors, such as the growing incidence of infectious diseases, higher healthcare awareness, and an aging population, are fueling market growth in developed regions. On the other hand, Asia Pacific is expected to grow at the highest CAGR during the forecast period due to the higher number of targeted populations, rising healthcare awareness, and government initiatives in the prevention of infectious diseases that would assist the market growth during the forecast period in that region.
